Jun 12, 2020
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA(TM) (tildrakizumab-asmn) in a Cross Section of People Living with Moderate-to-Severe Plaque Psoriasis
Jun 12, 2020
AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks
Jun 03, 2020
New First-in-Class Phase 3 TREMFYA® (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52
Apr 06, 2020
The Lancet Simultaneously Publishes Two Phase 3 Studies Detailing Comprehensive Efficacy and Safety of TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, in Psoriatic Arthritis
Feb 14, 2020
New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn's Disease Achieved Clinical Remission After Two Doses of STELARA® (ustekinumab)
Jan 14, 2020
New Head-to-Head Phase 3 Data Show SKYRIZI(TM) (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks
Nov 15, 2019
Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
Oct 21, 2019
Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Oct 21, 2019
STELARA® (ustekinumab) Data Demonstrate Long-Term Efficacy and Safety Results in Adults with Moderately to Severely Active Ulcerative Colitis in Phase 3 Extension Trial
Oct 17, 2019
Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab
Oct 07, 2019
Janssen Submits Application to U.S. FDA Seeking Approval of STELARA®(ustekinumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Sep 11, 2019
Interleukin Inhibitors Market Worth $74.6 Billion by 2026 | CAGR: 17.4%: Grand View Research, Inc.
Jul 25, 2019
Robust Use of Janssen's Tremfya and Positive Early Launch Metrics for AbbVie's Skyrizi May Threaten Growth of IL-17 Inhibitors in US Psoriasis Market, According to Spherix Global Insights
Jun 05, 2019
Lilly to Showcase Scientific Innovation within Dermatology Portfolio at 24th World Congress of Dermatology
Jun 04, 2019
Psoriatic Arthritis Market and Forecast Analysis 2035
May 15, 2019
NeuClone to Initiate Phase I Clinical Trial of Stelara (Ustekinumab) Biosimilar, the Second Biosimilar from the 10-product Portfolio with Serum Institute
May 14, 2019
Janssen Demonstrates Strong Commitment to Inflammatory Bowel Disease with Data from 25 Abstracts Presented at the 2019 Digestive Disease Week Annual Meeting
Apr 23, 2019
AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI(TM) (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
Apr 18, 2019
Health Canada Approves SKYRIZI(TM) (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
Mar 26, 2019
AbbVie Announces First Regulatory Approval of SKYRIZI(TM) (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan